Showing 3731-3740 of 10623 results for "".
CDC - Sodium Reduction: Time for Choice, Part 2
https://reachmd.com/programs/grand-rounds-nation/cdc-sodium-reduction-time-for-choice-part-2/6438/The vast majority of US adults consume more than double the recommended maximum of sodium, which is a direct cause of hypertension, a condition that affects nearly 1 in 3 Americans. Hypertension is not only a major contributor to cardiovascular disease (CVD), disability, and health disparities, butCDC - Sodium Reduction: Time for Choice, Part 1
https://reachmd.com/programs/grand-rounds-nation/cdc-sodium-reduction-time-for-choice-part-1/6437/The vast majority of US adults consume more than double the recommended maximum of sodium, which is a direct cause of hypertension, a condition that affects nearly 1 in 3 Americans. Hypertension is not only a major contributor to cardiovascular disease (CVD), disability, and health disparities, butCDC - TB & HIV: A Deadly Duo, Part 3
https://reachmd.com/programs/grand-rounds-nation/cdc-tb-hiv-a-deadly-duo-part-3/6392/The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB deathCDC - TB & HIV: A Deadly Duo, Part 2
https://reachmd.com/programs/grand-rounds-nation/cdc-tb-hiv-a-deadly-duo-part-2/6391/The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB deathRoflumilast Cream, 0.15%, for Atopic Dermatitis
https://reachmd.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulEquity in Sight: Addressing Disparities with Advanced Treatment Approaches
https://reachmd.com/specialty/retina/equity-in-sight-addressing-disparities-with-advanced-treatment-approaches/35745/Unmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
https://reachmd.com/programs/living-rheum/unmasking-patient-subtypes-in-sjogrens-disease-to-enable-personalized-care/36334/Rethinking MacTel: Cell-based Insights for Vision Preservation
https://reachmd.com/programs/cme/Rethinking-MacTel-Cell-Based-Insights-for-Vision-Preservation/35524/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.Cardio-Oncology Perspectives on COVID-19 from the Mayo Clinic
https://reachmd.com/programs/covid-19-frontlines/cardio-oncology-perspectives-on-covid-19-from-the-mayo-clinic/11364/Patients with pre-existing health conditions hold a much higher risk of severe complications from COVID-19. Here’s how specialists have responded.Long-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
https://reachmd.com/programs/medical-industry-feature/long-term-pnh-management-treatment-goals/35652/Patients with paroxysmal nocturnal hemoglobinuria (PNH) require lifelong therapy.1,2 Long-term data on an available treatment option can help address patient goals—not only in treating symptoms, but also long-term complications. Hear from Arati Chand, MD and Bhumika Patel, MD as they review two-year